Life Cycle

Original Research Article

# Shifts in COVID-19 vaccine acceptance rates among African countries: A systematic review and meta-analysis

# Yejoon Kim<sup>1#</sup>, Wongi Woo<sup>2#</sup>, Vincent Kipkorir<sup>3</sup>, Masoud Rahmati<sup>4</sup>, Ai Koyanagi<sup>5,6</sup>, Jae II Shin<sup>7\*</sup>, Lee Smith<sup>8</sup>

<sup>1</sup> Department of Education and Training, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

- <sup>2</sup> Department of Thoracic and Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- <sup>3</sup> Department of Human Anatomy, School of Medicine, University of Nairobi, Nairobi, Kenya
- <sup>4</sup> Department of Physical Education and Sport Sciences, Faculty of Literature and Human Sciences, Lorestan University, Khoramabad, Iran
- <sup>5</sup> Parc Sanitari Sant Joan de Deu/CIBERSAM, Universitat de Barcelona, Fundacio Sant Joan de Deu, Sant Boi de Llobregat, Barcelona, Spain
- <sup>6</sup> ICREA, Pg. Lluis Companys 23, Barcelona, Spain
- <sup>7</sup> Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea
- <sup>8</sup> Centre for Health Performance and Wellbeing, Anglia Ruskin University Cambridge, UK

#### Abstract

**Objective:** The few existing country-specific studies on vaccine hesitancy in Africa are limited by their focus on specific population groups such as health care workers or medical students. Thus, we aimed to provide a comparative systematic review and meta-analysis of COVID-19 vaccine acceptance rates in African countries and their predictors.

**Methods:** Fifteen studies on COVID-19 vaccine acceptance rates in African countries were reviewed in the PubMed/MEDLINE, Embase, and Google Scholar. Meta-analysis investigated the summary effect and inter-study heterogeneity of vaccine acceptance rates and influential factors.

**Results:** Overall, the COVID-19 vaccine acceptance rate was 71.0% (95% CI 64.0 to 77.0). However, as time passed, the vaccine acceptance rate showed a decrease (second half of 2020: 81%, first half of 2021: 67%). Also, the vaccine acceptance rates in urban areas were higher than in rural areas (urban: 82%, rural: 72%). When considering region, vaccine acceptance rates in Eastern and Southern African countries were higher than in Western and North African countries (East: 72%, South: 72%, West: 60%, and North: 52%). Finally, factors such as older age, male sex, and wealth were identified as factors associated with a more acceptive attitude toward vaccination.

**Conclusion:** COVID-19 vaccine acceptance rates demonstrated shifts and was affected by several factors. The rates decreased over time, were lower in rural (vs. urban) settings, and were relatively low in Northern and West African countries (vs. Southern and East African countries). We also found differences in vaccine acceptance rates by some socio-demographic characteristics. Targeting these characteristics, devising strategies to improve vaccine uptake in Africa could help improve vaccination rates.

Keywords: COVID-19, vaccine hesitancy, vaccine acceptance, African countries

**1. Introduction** 

Received: date: Mar 2, 2023. Revised date: Apr 12, 2023. Accepted date: Apr 22, 2023. Published date: May 10, 2023.

# These authors contributed equally to this work

More than 676 million people have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and 6.8 million people have died from the disease worldwide (as of March 13, 2023).[1] In Africa, more than 12 million people have been infected with COVID-19

#### \*Correspondence: Jae Il Shin E-mail: shinji@yuhs.ac

#### ORCID Jae Il Shin https://orcid.org/0000-0003-2326-1820

Copyright © 2023 Life Cycle. This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited (CC-BY-NC). and more than 250,000 mortalities have been reported (Africa CDC COVID-19 Dashboard, March 13, 2023).[2] Consequently, there has been a growing burden on existing health systems relative to the number of cases. Several vaccines against COVID-19 have been developed and 11.7 billion doses have already been administered in a bid to quell the growing numbers of COVID-19 cases (COVID19 map - Johns Hopkins Coronavirus Resource Center, August 22, 2022).[1] Failure of vaccine uptake however continually propagates the growing prevalence and worse prognosis of the disease, especially in countries across Africa, contributing to ~2.4% of COVID-19 associated mortality rates in the continent.[3] Low and middle-income countries remain largely affected by higher rates of hesitancy owing to several factors such as a lack of knowledge on vaccine efficacy as well as other socio-cultural and historical dynamics.[3]

Historically, vaccines have been proven to be very successful and cost-effective tools for preventing diseases.[4] Herd immunity can be achieved when enough people receive an effective vaccine which also protects those who are susceptible to the virus.[5] As expected, the research focus on COVID-19 has shifted from treatment of the disease to the role of vaccines and implications brought about by the budding rates of vaccine hesitancy. However, these studies have mainly been conducted in developed countries such as the United States and European countries, with relatively few studies focusing on developing countries such as African nations.[6] The few existing country-specific studies on vaccine hesitancy in Africa are limited by their focus on specific population groups such as health care workers or medical students. Subsequently, the true prevalence of vaccine hesitancy in Africa remains relatively unknown.

Hence this systematic review and meta-analysis was conducted in order to assess the pooled vaccine acceptance rates and factors influencing vaccine acceptance. We expect that our metaanalysis can provide clinicians with a thorough understanding of vaccine rejection rates in African countries and the influential factors.

# 2. Materials and methods

#### 2.1 Literature search strategy and study selection

We followed the guideline of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist for this systematic review (Supplementary Table S1).[7] Two investigators (Y.K. and W.W.) searched the literature in PubMed/Medline to find the original studies that conducted surveys of COVID-19 vaccine hesitancy in Africa. The search terms were "(covid-19 vaccine) AND (hesitancy OR refusal OR willingness) AND survey", and the date of the last search was 19 December 2021. If there were any discrepancy for the inclusion or exclusion of the study, the two investigators (Y.K. and W.W.) discussed and resolved it. The full method of screening papers is presented in Fig. 1.

The eligibility criteria for inclusion were: (1) survey was conducted of the general population; (2) main goal of the paper was to find the hesitancy/acceptance rate of COVID-19 vaccine; (3) survey was conducted in Africa; and (4) publication language was English. The exclusion criteria were: (1) survey was conducted with healthcare workers; and (2) survey was





#### Fig. 1. Flow chart of literature search

conducted with specific populations such as military workers, caregivers, and young or old populations. Our initial search yielded 795 results, but we eventually included 15 studies that met our inclusion criteria.

# 2.2 Data extraction

For each eligible study, we extracted the following data: country/countries where the survey was conducted, author, participants, survey methods, period of survey, demographic data, total number of respondents, COVID-19 vaccine hesitancy/acceptance rate, and predictive factors related to vaccine acceptance rate.

We also searched the actual vaccination rates in the country at the time the study was conducted, and 3 and 6 months after that using Our World in Data – COVID vaccinations.[8]

# 2.3 Analyses of studies and statistical analysis

The data for each study are presented in Table 1. To estimate the relationship between vaccine acceptance and each variable, we used an estimation of 95% confidence interval (CI) using random-effect models (DerSimonian and Laird, 2015; Lau et al., 1997). The random-effect model provides the weighted average of the effect sizes of a group of studies with the assumption that each study supplies information about a different effect size (Ioannidis et al., 2011). We evaluated the between-study heterogeneity using the I<sup>2</sup> metric of inconsistency. I<sup>2</sup> is the ratio of the between-study variance over the sum of the within-study and between-study variances, ranging from 0–100%. I<sup>2</sup> values over 50% usually represent significant heterogeneity (Higgins et al., 2003). Publication bias was not assessed because studies included in the proportion meta-analyses were non-comparable. All analyses were conducted using R version 4.1.0 (R Foundation for Statistical Computing, Vienna, Austria).[9]

Table 1. Demographic information and summary of the studies on vaccine hesitancy in African countries

	Author	Country	N	Period	Male (%)	Age	Education	Urban residents (%)	2020 GDP (USD Billion)	Acceptance rate	Total vaccination rate at survey (%)	Vaccina- tion rate (%, after 3 months)	Vaccina- tion rate (%, after 6 months)
1	Acheam- pong	Ghana	2,345	February 23rd to 28th 2021	1,223/ 2,345 (52%)	Under 35 : 55% Under 55 : 87% n=2,345	Primary or less : 0 % University or above : 93%	-	68.532	1,197/2,345 (51%)	-	2.69*	2.73*
2	Ahmed	Somalia	4,543	December 2020 to January 2021	2,837/ 4,543 (62.4%)	23.5 (6.4) n=4,543	Primary or less : 2.3% University or above : 86.2%	89.4	6.965	3,488/4,543 (76.8%)	-	0.79*	0.91*
3	Alhassan	Ghana	1,556	September 18th to October 23rd, 2020	777/1,534 (50.7%)	32.77 (9.72) n=1,445	Primary or less : 17.2% University or above : 67.9%	-	68.532	697/1,077 (64.7%)	-	-	2.69**
4	Anjorin	Africa	5,416	February and March 2021	2,790/ 5,200 (53.7%)	Under 35 : 60.8% Under 55 : 92.5% n=5,200	Primary or less : 1.3% University or above : 77.7%	67.3	NA	3,277/5,211 (63%)	0.29	1.87	5.11
5	Belsti	Ethiopia	1,184	February to March 2021	1,086/ 1,184 (91.7%)	28.86 (3.90) n=1184 35 (11.5)	Primary or less : 0 % University or above : 78.7%	87.2	107.645	372/1,184 (31.4%)	-	1.98**	2.46
6	Ditekem- ena	Congo	4,131	August 24th to September 8th 2020	1,304/ 4,131 (31.6%)	Under 30 : 40.9% Under 50 : 87.8% n=4,131	Primary or less : less than 71% University or above : 29%	-	10.187	2,310/4,131 (55.9%)	-	-	2.35
7	Dula	Moza- mbique	1,878	March 11th to 20th 2021	1,128/ 1,878 (60.0%)	Under 35 : 58.3% Under 60 : 96.6% n=1878		-	14.019	1,340/1,878 (71.4%)	-	1.06*	5.92

Table 1. continued

	Author	Country	N	Period	Male (%)	Age	Education	Urban residents (%)	2020 GDP (USD Billion)	Acceptance rate	Total vaccination rate at survey (%)	Vaccina- tion rate (%, after 3 months)	Vaccina- tion rate (%, after 6 months)
8	Elgendy	Egypt	871	April and May 2021	406/871 (46.6%)	Under 35 : 29.3% Under 55 : 94.8% n=871	Primary or less : 0.0% University or above :100%	74.1	365.253	?/871 (86%)	1.02*	3.63%	17.77
9	Kanyanda	Mali	1,765	October to November 2020	?/1,765 (78.9%)	Under 30 :13.8% Under 60 : 84.1% n=1765	Primary : 30.9%	66.3	17.465	64.5% (95% CI 61.3% to 67.8%) n=1,765	-	-	0.34*
	Kanyanda	Burkina Faso	1,945	December 2020	?/1,742 (78.7%)	Under 30 : 11.3% Under 60 : 89.9% n=1742	Primary : 32.4%	72	17.934	79.6% (95% CI 77.0% to 82.3%) n=1,944	-	-	0.50**
	Kanyanda	Malawi	1,589	October to November 2020	?/1,589 (59.8%)	Under 30 : 27.8% Under 60 : 90.5% n=1589	Primary : 50.2%	36.8	12.182	82.7% (95% CI 80.0% to 85.4%) n=1,589	-	-	1.83**
	Kanyanda	Uganda	2,129	December 2020	?/2,129 (50.7%)	Under 30 : 15.3% Under 60 : 81.4% n=2129	Primary 51.1%	25.8	37.6	84.5% (95% CI 82.2% to 86.8%) n=2,129	-	-	1.08*
	Kanyanda	Ethiopia	2,701	September 2020	?/ 2,701 (62.7%)	Under 30 : 29.4% Under 60 : 91.7% n=2701	Primary 52.9%	71.9	107.645	97.9% (95% CI 97.2% to 98.6%) n=2,701	-	-	1.98**
	Kanyanda	Nigeria	1,766	October to November 2020	?/1,766 (72.3%)	Under 30 : 13.5% Under 60 : 82.5% n=1766	Primary 75.1%	39.3	432.294	86.2% (95% CI 83.9% to 88.5%) n=1,766	-	-	0.91*
10	Kollamp- arambil	South Africa	5,629	February and March 2021	2,140/ 4,440 (48.2%)	40.47 (15.04) n=4440	-	76	335.442	3,976/5,613 (70.84%)	0.13	6.06*	16.23
11	McAbee	Zim- babwe	551	May 2021	152/551 (27.6%)	Under 30 : 24.9% Under 55 : 75.3% n=551 29.35±10.78	-	-	18.051	410/551 (74.4%)	3.86	4.63	19.36
12	Omar	Egypt	1,011	January 7th to March 30th 2021	417/1,011 (41.2%)	Under 30 : 55.1% Under 50 : 95.7% n=1,011	Primary or less : 6.8% University or above : 70.3%	54.3	365.253	259/1,011 (25.6%)	-	1.51*	4.90*
13	Orangi	Kenya	4136	February 2021	1,355/ 4,136 (32.8%)	Under 35 : 33.3% Under 55 : 91.6% n=4044	Primary or less : 70.7% University or above : 7.4%	44	101.014	2,627/4,136 (63.5%)	-	1.76*	2.30

rable r. commuted	Table	1.	continued
-------------------	-------	----	-----------

	Author	Country	N	Period	Male (%)	Age	Education	Urban residents (%)	2020 GDP (USD Billion)	Acceptance rate	Total vaccination rate at	Vaccina- tion rate (%, after 3 months)	Vaccina- tion rate (%, after
14	Oyekale	Kenya	10702	January 15th to June 13th 2021	5,648/ 10,702 (52.8%)	Under 35 : 40.9% Under 55 : 83.9 n=10702	Primary or less : 39.3% University or above : 15.4%	52.7	101.014	8,284/ 10,702 (77.41%)	1.76**	1.83	5.20
15	Oyekale	Ethiopia	2178	February 1st to 23rd, 2021	1,355/ 2,178 (62.2%)	Under 60 : 95.36% Under 30 : 29.85% n=2178	-	75.3	107.645	2,011/2,167 (92.8%)	-	-	1.56*

#### 3. Results

#### 3.1 General characteristics of the included studies

A total of 15 studies met the inclusion criteria and were employed in the present systematic review and meta-analyses as outlined in the PRISMA flow chart (Fig. 1). Fifteen studies investigated the acceptance rate of SARS-CoV-2 vaccines among people in African countries, with the demographic information for each study is provided in Table 1.[10]-[24]

Fifteen studies, in which the number of investigated populations varied from 551 to 10,702, were conducted in several African countries, including Ghana, Nigeria, Morocco, Egypt, Mozambique, Zimbabwe, Somalia, and Ethiopia. Most of the surveys were conducted online (survey tools, Microsoft forms, REDCap software, Google forms, or independent programs; n=10) or by phone (n=4). Three studies were conducted in the second half of 2020, and 12 studies were conducted in the first half of 2021.

In some cases, actual vaccination rates data by country for the desired date (at survey, 3,6 months after) were not available. In this case, we used data from the closest date with data after that date. If there was a difference within one month, it is marked as <sup>\*</sup>, and if there was a difference of more than one month, it is marked as <sup>\*\*</sup>.

#### 3.2 Vaccine acceptance rates

The pooled SARS-CoV-2 vaccination acceptance rate by studies based on countries are shown in Fig. 2. In the overall study, the SARS-CoV-2 vaccine acceptance was 71% (95% CI 64-77).

A meta-analysis was conducted based on the study period, residential area, gender, language, location, and Gross Domestic Product. The results of the meta-analysis are shown in Fig. 3-5.

First, the vaccine acceptance rate according to the study period was 81(95% CI 67-90) in the second half of 2020, and 67% (95% CI 60-73) in the first half of 2021 (Fig. 3). As time passed, the vaccine acceptance rate was found to decrease.

Second, the vaccine acceptance rate according to residential area was 72% (95% CI 52-86) in rural areas (studies with urban participants < 60%) and 82% (95% CI 66-91) in urban areas (Fig. 4).

	_					Weight	Weight
Study	Events	Total		Proportion	95%-CI	(fixed)	(random)
Acheampong (Ghana), 2021 First half	1197	2345	+	0.51	[0.49; 0.53]	5.6%	3.0%
Ahmed (Somalia), 2021 First half	3488	4543		0.77	[0.76; 0.78]	7.7%	3.0%
Anjorin (Morocco), 2021 First half	210	317		0.66	[0.61; 0.71]	0.7%	2.9%
Anjorin (Ghana), 2021 First half	269	443		0.61	[0.56; 0.65]	1.0%	3.0%
Anjorin (Rwanda), 2021 First half	205	321		0.64	[0.58; 0.69]	0.7%	3.0%
Anjorin (Kenya), 2021 First half	88	149		0.59	[0.51; 0.67]	0.3%	2.9%
Anjorin (Egypt), 2021 First half	408	625		0.65	[0.61; 0.69]	1.3%	3.0%
Anjorin (Nigeria), 2021 First half	678	1031		0.66	[0.63; 0.69]	2.2%	3.0%
Anjorin (Sudan), 2021 First half	302	419		0.72	[0.68; 0.76]	0.8%	3.0%
Anjorin (Cameroon), 2021 First half	135	409	I	0.33	[0.28; 0.38]	0.9%	3.0%
Anjorin (South Africa), 2021 First half	390	520		0.75	[0.71; 0.79]	0.9%	3.0%
Anjorin (Africans in Diaspora), 2021 First half	215	324		0.66	[0.61; 0.71]	0.7%	3.0%
Anjorin (DRC Congo), 2021 First half	187	397	E	0.47	[0.42; 0.52]	0.9%	3.0%
Anjorin (Liberia), 2021 First half	65	77		0.84	[0.74; 0.92]	0.1%	2.7%
Anjorin (Malawi), 2021 First half	28	38		0.74	[0.57; 0.87]	0.1%	2.6%
Anjorin (Tanzania), 2021 First half	61	86		0.71	[0.60; 0.80]	0.2%	2.8%
Anjorin (Other african), 2021 First half	36	55		0.65	[0.51; 0.78]	0.1%	2.7%
Belsti (Ethiopia), 2021 First half	560	1184	-	0.47	[0.44; 0.50]	2.8%	3.0%
Dula (Mozambique), 2021 First half	1340	1878	in .	0.71	[0.69; 0.73]	3.6%	3.0%
Kollamparambil (South Africa), 2021 First hal	f 3976	5613		0.71	[0.70; 0.72]	11.0%	3.0%
McAbee (Zimbabwe), 2021 First half	410	551		0.74	[0.71; 0.78]	1.0%	3.0%
Omar (Egypt), 2021 First half	259	1011	+	0.26	[0.23; 0.28]	1.8%	3.0%
Orangi (Kenya), 2021 First half	2627	4136		0.64	[0.62; 0.65]	9.1%	3.0%
Oyekale (Kenya), 2021 First half	8284	10702	•	0.77	[0.77; 0.78]	17.8%	3.0%
Oyekale (Ethiopia), 2021 First half	2011	2167	-	0.93	[0.92; 0.94]	1.4%	3.0%
Alhassan (Ghana), 2020 Second half	697	1077	-	0.65	[0.62; 0.68]	2.3%	3.0%
Ditekemena (Congo), 2020 Second half	2310	4131		0.56	[0.54; 0.57]	9.7%	3.0%
Kanyanda (Mali), 2020 Second half	1138	1765	+	0.64	[0.62; 0.67]	3.8%	3.0%
Kanyanda (Burkina Faso), 2020 Second half	1547	1944	+	0.80	[0.78; 0.81]	3.0%	3.0%
Kanyanda (Malawi), 2020 Second half	1314	1589	+	0.83	[0.81; 0.85]	2.2%	3.0%
Kanyanda (Uganda), 2020 Second half	1799	2129	+	0.84	[0.83; 0.86]	2.7%	3.0%
Kanyanda (Ethiopia), 2020 Second half	2644	2701		+ 0.98	[0.97; 0.98]	0.5%	2.9%
Kanyanda (Nigeria), 2020 Second half	1522	1766	+	0.86	[0.84; 0.88]	2.0%	3.0%
Elgendy (Egypt), 2020 First half	749	871	+	0.86	[0.84; 0.88]	1.0%	3.0%
Fixed effect model		57314		0.70	[0.69; 0.70]	100.0%	
Random effects model			<b></b>	0.71	[0.64; 0.77]		100.0%
Heterogeneity: / <sup>2</sup> = 99%, T <sup>2</sup> = 0.7833, p = 0							
			0.3 0.4 0.5 0.6 0.7 0.8 0.9				

#### Fig. 2. SARS-CoV-2 vaccination acceptance rate in Africa by studies and countries.

#### A. 2020 Second Half (July to December, 2020)

Study	Events	Total						Pro	oportion	95%-CI	Weight (fixed)	Weight (random)	
Alhassan (Ghana), 2020 Second half	697	1077			1				0.65	[0.62; 0.68]	8.9%	12.5%	
Ditekemena (Congo), 2020 Second half	2310	4131	+		1				0.56	[0.54; 0.57]	36.9%	12.5%	
Kanyanda (Mali), 2020 Second half	1138	1765		-#	1				0.64	[0.62; 0.67]	14.7%	12.5%	
Kanyanda (Burkina Faso), 2020 Second half	1547	1944			1	-			0.80	[0.78; 0.81]	11.5%	12.5%	
Kanyanda (Malawi), 2020 Second half	1314	1589				÷	-		0.83	[0.81; 0.85]	8.2%	12.5%	
Kanyanda (Uganda), 2020 Second half	1799	2129			1		-		0.84	[0.83; 0.86]	10.1%	12.5%	
Kanyanda (Ethiopia), 2020 Second half	2644	2701			1			+	0.98	[0.97; 0.98]	2.0%	12.4%	
Kanyanda (Nigeria), 2020 Second half	1522	1766					*		0.86	[0.84; 0.88]	7.6%	12.5%	
Fixed effect model		17102			\$				0.71	[0.70; 0.72]	100.0%		
Random effects model				_	_				0.81	[0.67; 0.90]		100.0%	
Heterogeneity: $l^2 = 100\%$ , $\tau^2 = 1.2424$ , $p < 0.01$			Г		Γ								
			0.6	5 C	).7	0.8	0.9						

#### B. 2021 First Half (January to June, 2021)

Study	Events	Total		Proportion	95%-CI	Weight (fixed)	Weight (random)
Acheampong (Ghana), 2021 First half	1197	2345	+	0.51	[0.49; 0.53]	7.5%	4.0%
Ahmed (Somalia), 2021 First half	3488	4543		0.77	[0.76; 0.78]	10.4%	4.0%
Anjorin (Morocco), 2021 First half	210	317		0.66	[0.61; 0.71]	0.9%	3.9%
Anjorin (Ghana), 2021 First half	269	443		0.61	[0.56; 0.65]	1.4%	3.9%
Anjorin (Rwanda), 2021 First half	205	321		0.64	[0.58; 0.69]	1.0%	3.9%
Anjorin (Kenya), 2021 First half	88	149		0.59	[0.51; 0.67]	0.5%	3.8%
Anjorin (Egypt), 2021 First half	408	625		0.65	[0.61; 0.69]	1.8%	3.9%
Anjorin (Nigeria), 2021 First half	678	1031	-	0.66	[0.63; 0.69]	3.0%	4.0%
Anjorin (Sudan), 2021 First half	302	419		0.72	[0.68; 0.76]	1.1%	3.9%
Anjorin (Cameroon), 2021 First half	135	409	- <b>-</b>	0.33	[0.28; 0.38]	1.2%	3.9%
Anjorin (South Africa), 2021 First half	390	520		0.75	[0.71; 0.79]	1.3%	3.9%
Anjorin (Africans in Diaspora), 2021 First half	215	324		0.66	[0.61; 0.71]	0.9%	3.9%
Anjorin (DRC Congo), 2021 First half	187	397	-	0.47	[0.42; 0.52]	1.3%	3.9%
Anjorin (Liberia), 2021 First half	65	77		- 0.84	[0.74; 0.92]	0.1%	3.4%
Anjorin (Malawi), 2021 First half	28	38		0.74	[0.57; 0.87]	0.1%	3.2%
Anjorin (Tanzania), 2021 First half	61	86		0.71	[0.60; 0.80]	0.2%	3.6%
Anjorin (Other african), 2021 First half	36	55		0.65	[0.51; 0.78]	0.2%	3.5%
Belsti (Ethiopia), 2021 First half	560	1184	-	0.47	[0.44; 0.50]	3.8%	4.0%
Dula (Mozambique), 2021 First half	1340	1878	-	0.71	[0.69; 0.73]	4.9%	4.0%
Kollamparambil (South Africa), 2021 First half	3976	5613		0.71	[0.70; 0.72]	14.9%	4.0%
McAbee (Zimbabwe), 2021 First half	410	551		0.74	[0.71; 0.78]	1.4%	3.9%
Omar (Egypt), 2021 First half	259	1011	+	0.26	[0.23; 0.28]	2.5%	3.9%
Orangi (Kenya), 2021 First half	2627	4136		0.64	[0.62; 0.65]	12.3%	4.0%
Oyekale (Kenya), 2021 First half	8284	10702	-	0.77	[0.77; 0.78]	24.1%	4.0%
Oyekale (Ethiopia), 2021 First half	2011	2167		+ 0.93	[0.92; 0.94]	1.9%	3.9%
Elgendy (Egypt), 2021 First half	749	871	+	0.86	[0.84; 0.88]	1.4%	3.9%
Fixed effect model		40212		0.69	[0.69; 0.70]	100.0%	
Random effects model			$\diamond$	0.67	[0.60; 0.73]		100.0%
Heterogeneity: $I^2 = 99\%_1^2 = 0.5472_1^2 p = 0$							
			0.3 0.4 0.5 0.6 0.7 0.8 0.	9			

# Fig. 3. SARS-CoV-2 vaccine acceptance rate according to temporal change (A. 2020 Second Half, B. 2021 First Half)

#### A. Rural area (studies with the urbran residents under 60%)

Study	Events	Total							Proportion	95%-CI	Weight (fixed)	Weight (random)
Kanyanda (Uganda), 2020 Second half	1799	2129					8	*	0.84	[0.83; 0.86]	7.5%	16.7%
Kanyanda (Malawi), 2020 Second half	1314	1589						*	0.83	[0.81; 0.85]	6.1%	16.7%
Kanyanda (Nigeria), 2020 Second half	1522	1766						+	0.86	[0.84; 0.88]	5.6%	16.6%
Orangi (Kenya), 2021 First half	2627	4136							0.64	[0.62; 0.65]	25.6%	16.7%
Oyekale (Kenya), 2021 First half	8284	10702							0.77	[0.77; 0.78]	50.1%	16.7%
Omar (Egypt), 2021 First half	259	1011	-				1		0.26	[0.23; 0.28]	5.2%	16.6%
Fixed effect model		21333					è		0.74	[0.73; 0.74]	100.0%	
Random effects model					-		-	2.0	0.72	[0.52; 0.86]		100.0%
Heterogeneity: $l^2 = 100\%$ $\tau^2 = 1.1950$ p	< 0.01											
, ,			0.3	0.4	0.5	0.6 0.1	70.	8				

#### B. Urban area (studies with the urbran residents $\geq$ 60%)

Study	Events	Total					Proportion	95%-CI	Weight (fixed)	Weight (random)
Kanyanda (Mali), 2020 Second half	1138	1765	-	- i			0.64	[0.62; 0.67]	12.3%	12.5%
Kanyanda (Ethiopia), 2020 Second half	2644	2701				+	0.98	[0.97; 0.98]	1.7%	12.4%
Kanyanda (Burkina Faso), 2020 Second half	1547	1944		- i -	нÌ –		0.80	[0.78; 0.81]	9.6%	12.5%
Elgendy (Egypt), 2020 First half	749	871					0.86	[0.84; 0.88]	3.2%	12.5%
Oyekale (Ethiopia), 2021 First half	2011	2167				+	0.93	[0.92; 0.94]	4.4%	12.5%
Kollamparambil (South Africa), 2021 First half	3976	5613		11			0.71	[0.70; 0.72]	35.2%	12.5%
Belsti (Ethiopia), 2021 First half	560	1184					0.47	[0.44; 0.50]	9.0%	12.5%
Ahmed (Somalia), 2021 First half	3488	4543					0.77	[0.76; 0.78]	24.6%	12.5%
Fixed effect model		20788					0.74	[0.73; 0.74]	100.0%	
Random effects model					:	-	0.82	[0.66; 0.91]		100.0%
Heterogeneity: $l^2 = 99\% T^2 = 1.4930 p < 0.01$						1		- / -		
• • • • • • • • • • • • • • • • • • •			05 06	07 0	8 0	a				

#### Fig. 4. SARS-CoV-2 vaccine acceptance rate according to residential area (A. Rural areas, B. Urban areas)

Α									Weig	ht	Weight
Study	Events	Total				Pr	oportion	95%-0	CI (fixe	d) (r	andom)
Anjorin (Cameroon), 2021 First half Acheampong (Ghana), 2021 First half Anjorin (Ghana), 2021 First half Anjorin (Liberia), 2021 First half Anjorin (Nigeria), 2021 First half	135 1197 269 65 678	409 2345 443 77 1031	-*	-		. <u> </u>	0.33 0.51 0.61 0.84 0.66	[0.28; 0.3 [0.49; 0.5 [0.56; 0.6 [0.74; 0.9 [0.63; 0.6	8] 8.8 3] 57.2 5] 10.3 2] 1.0 9] 22.7	% % % %	20.4% 20.6% 20.4% 18.1% 20.5%
Fixed effect model Random effects model Heterogeneity: $I^2 = 98\%$ , $\tau^2 = 0.6851$ , $p <$	0.01	4305	0.3 0.4	0.5 0.6	0.7 0.8	0.9	0.54 0.60	[0.53; 0.5 [0.41; 0.7	6] 100.0 6]	% 	100.0%
В									Woi	abt	Woight
Study E	vents T	otal				Pi	roportion	95%-	CI (fix	ed) (	(random)
Anjorin (Morocco), 2021 First half Anjorin (Egypt), 2021 First half Omar (Egypt), 2021 First half	210 408 259 1	317 625 011 -			-	æ— ⊢	0.66 0.65 0.26	[0.61; 0. [0.61; 0.6 [0.23; 0.2	71] 17. 59] 35. 28] 47.	5% 0% 5%	33.2% 33.4% 33.5%
Fixed effect model Random effects model Heterogeneity: $l^2 = 99\%$ , $T^2 = 0.9798$ , p	1 < 0.01	953	0.3	0.4 0.5	0.6	0.7	0.46 - 0.52	[0.43; 0.4 [0.26; 0.7	48] 100. 77]	0% 	100.0%
с											
Study	E	vents	Total				Proport	tion 9	м 5%-СІ (	fixed	t Weight ) (random)
Dula (Mozambique), 2021 First half Anjorin (South Africa), 2021 First half Kollamparambil (South Africa), 2021 Fir McAbee (Zimbabwe), 2021 First half	st half	1340 390 3976 410	1878 — 520 5613 - 551	-			- 0	0.71 [0.69 0.75 [0.71 0.71 [0.70 0.74 [0.71	0.73] 0.79] 0.72] 0.78]	22.0% 5.6% 6.4% 6.0%	30.1% 15.1% 38.9% 15.9%
Fixed effect model Random effects model Heterogeneity: $I^2 = 55\%$ , $\tau^2 = 0.0051$ , $\rho = 0$	0.09		<b>8562</b>	0.7 0.72	0.74 0.	76 0.7	( ( 78	0.71 [0.70; 0.72 [0.70;	0.72] 10 0.74]	0.0%	100.0%
D									We	ight	Weight
Study E	vents	Total				F	Proportio	n 95%	S-CI (fi	xed)	(random)
Ahmed (Somalia), 2021 First half Anjorin (Rewanda), 2021 First half Anjorin (Kenya), 2021 First half Anjorin (Malawi), 2021 First half Anjorin (Tanzania), 2021 First half Belsti (Ethiopia), 2021 First half Orangi (Kenya), 2021 First half Oyekale (Kenya), 2021 First half Oyekale (Ethiopia), 2021 First half	3488 205 88 61 560 2627 8284 1 2011	4543 321 149 38 86 1184 4136 0702 2167					0.7 0.6 0.5 0.7 0.7 0.7 0.4 0.6 0.7 0.9	7 [0.76; 0 4 [0.58; 0 9 [0.51; 0 4 [0.57; 0 1 [0.60; 0 7 [0.44; 0 4 [0.62; 0 7 [0.77; 0 3 [0.92; 0	.78] 19 .69] 1 .67] ( .87] ( .80] ( .50] 7 .65] 22 .78] 44 .94] 3	9.2% 1.8% 0.9% 0.2% 0.4% 7.0% 2.7% 1.4% 8.4%	11.6% 11.3% 11.1% 9.4% 10.6% 11.5% 11.6% 11.6%
Fixed effect model Random effects model Heterogeneity: $l^2 = 99\%$ , $\tau^2 = 0.5702$ , p	< 0.01	3326			<u> </u>	_	0.7 0.7	3 [0.73; 0 2 [0.60; 0	.74] 100 .81]	0.0% 	100.0%

Fig. 5. SARS-CoV-2 vaccine acceptance rate according to residential areas (A. Western African countries, B. Northern African countries, C. Southern African countries, D. Eastern African countries)

0.5 0.6 0.7 0.8 0.9

Third, the vaccination rates according to region were 60% (95% CI 41-76) in West African countries, 72% (95% CI 70-74) in Southern African countries, 52% (95% CI 26-77) in Northern African countries, and 72% (95% CI 60-81) in Eastern African countries (Fig. 5).

The actual vaccination rate by country varied from 0.00 to 9.80% at the time of the survey and 0.09 to 50.98% six months after the survey. However, this was not significantly related to the vaccine acceptance rate investigated in the study.

# 3.3 Predictive factors related to vaccine acceptance rates

Factors related to vaccine hesitancy from studies are shown in Table 2. Factors analyzed in two or more studies are summarized in Table 2. Factors such as older age, male sex, wealth, higher awareness of COVID-19 related information, currently working, working in health-related job, suffering chronic disease, previously tested for or COVID-19 were mainly identified as factors showing a more acceptive attitude toward vaccination. On the other hand, lower education was identified as a hesitance factor for vaccination.

Table 2. Factors shown to be related to vaccine acceptance from studies

	Prognostic factor, multivariate analysis									
Acceptance factor	Yes(acceptance)	No(hesitancy)	Meaningless	Nonreporting						
Relatively old age	[1,4,5,7,14,15]	[3,10]	[2,13]	[6,8,9,11,12]						
Married	[4,5]	[3,12,13]	[7,10]	[1,2,6,8,9,11,14,15]						
Male	[1,2,3,5,11,15]	[4,12,14]	[7,9,10,13]	[6,8]						
Rural regions	[5,9,12,15]	[3,4,13]	[1,2,10]	[6,7,8,11,14]						
Lower education	[5,9]	[3,6,10,11,12,13,14]	[1,2,4]	[7,8,15]						
Richer households	[4,6,10]	[9]	[13]	[1,2,3,5,7,8,11,12,14,15]						
Higher awareness of COVID-19 related information	[2,7,10,11,13]	[Ø]	[Ø]	[1,3,4,5,6,8,9,12,14,15]						
Currently working	[4,15]	[Ø]	[2,10]	[1,3,5,6,7,8,9,11,12,13,14]						
Health-related job	[2,5,6,7]	[Ø]	[Ø]	[1,3,4,8,9,10,11,12,13,14,15]						
Suffering chronic disease	[6,7]	[Ø]	[2]	[1,3,4,5,8,9,10,11,12,13,14,15]						
Religious individuals	[4,6]	[10]	[Ø]	[1,2,3,5,7,8,9,11,12,13,14,15]						
Muslims	[5]	[3]	[Ø]	[1,2,4,6,7,8,9,10,11,12,13,14,15]						
Previously tested for COVID-19	[6,7]	[Ø]	[Ø]	[1,2,3,4,5,8,9,10,11,12,13,14,15]						

		Prognostic fa	actor, multivariate an	alysis
Acceptance factor	Yes(acceptance)	No(hesitancy)	Meaningless	Nonreporting
Concerns of side effects and effectiveness	[Ø]	[5,13]	[Ø]	[1,2,3,4,6,7,8,9,10,11,12,14,15]

#### Table 2. Continued

# 4. Discussion

With the prolongation of the COVID-19 pandemic, the importance of vaccination cannot be understated.[25] In order to increase vaccination rates in any country, it is important to first analyse the vaccination hesitancy rates and identify the factors that propagate rejection of the vaccine. A proper understanding of this helps tailor appropriate strategies to avert the budding rate of vaccine hesitancy.

This study examined COVID-19 vaccine acceptance among African countries. We found that approximately 7 out of 10 (71%) Africans wanted to be vaccinated. This is relatively lower than around the 80% that was observed in the American population according to a 2021 randomized controlled trial, conducted in the United States.[26] Another article published in December 2020 however stated that vaccine acceptance rate in the US was as low as 56.9%. [27] The difference between the two studies seems to have been caused by the faction of participants who were unsure rather than hesitant to receive the vaccine. However, unlike America, where widespread studies and education were conducted on the role of vaccines, the lower rates observed of vaccine hesitancy in Africa have been attributed to a lack of knowledge on vaccine efficacy, socio-cultural and historical aspects.[3]

We also found that vaccine acceptability was also influenced by several other factors. First, depending on the study period, it was possible to see a trend of decreasing vaccine acceptance over time, from 81% in the second half of 2020 to 67% in the first half of 2021. The same trend was seen in a meta-analysis of 28 representative samples from 13 countries (UK, North America, France, Australia, China, Denmark, Germany, Italy, Ireland, Netherlands, Poland and Portugal) on COVID-19 vaccine hesitation.[28] This phenomenon was also seen in vaccines other than the coronavirus vaccine. In 2009, a study of the H1N1 influenza vaccine in France showed a sharp increase in negative attitudes toward the vaccine over time.[29] This can be due to the decrease in people's fear of disease as a result of increasing information on the new disease and more information on the side effects of vaccines.

Second, the vaccine acceptance rate in rural areas was 72%, lower than in urban areas (82%). This is in contrast to a study conducted in the United States in 2021, which found that rural people (16.3%) were less likely to reject COVID-19 vaccines as compared to urban people (19.7%).[30] The difference between the two studies may be that there are people who neither accept nor reject vaccination. Alternatively, as shown in a study conducted in the United States, people living in rural areas may be less likely to participate in health promoting behaviors[31], which leads to less interest in the vaccine per se. This may be the reason of low rates for

acceptance.

Third, the vaccine acceptance rate in Northern African countries was 52%, relatively lower than Western African countries (60%) or Southern African and Eastern African countries (72%). These findings could have been influenced by the number of studies conducted in each of the regions with a possibility of regional underreporting of vaccine hesitancy. Hence, a need for more research on vaccine hesitancy, especially in Northern African countries, are warranted. We also found differences in vaccine acceptance rates and some socio-demographic characteristics. Older age, male, wealth, health-related workers, and chronic medical conditions were mainly identified as factors contributing to a receptive attitude toward vaccination. Interestingly, low educational attainment was identified as a factor related with hesitancy to receive the vaccine. Among these factors, the low acceptance rate of women's vaccines tended to be consistent with previous studies.[32]-[34] Overall, it is thought that people who are interested in health activities and those who will suffer greatly from the COVID-19 are favorable to vaccination, and those who are worried about vaccines tend to refuse vaccination.

#### 4.1 Advantages and singularities of this study

There are several articles on vaccine acceptance rates in developed countries such as European countries and the USA, but insufficient amounts of studies have been done on African countries. As the COVID-19 situation is being prolonged, vaccinations in developing countries such as African nations are considered important.

We applied a meta-analysis of studies conducted in African countries. To our knowledge, this study is the first attempt to meta-analyse recent vaccine rejection related studies conducted in African countries and to demonstrate trends and associated factors. Therefore, this meta-analysis will provide a more systematic understanding of vaccine acceptance rate, rejection factors, and the appropriate strategy in African countries.

This study was also the first to investigate how much the previously investigated vaccine acceptance rate is related to the actual vaccination rate. It has the advantage of being able to discover how much the surveyed vaccine acceptance rate is related to the actual vaccination rate.

#### 4.2 Opinions on the results and hypotheses of other studies

Several studies have reported that age, gender, and residential area are related to the vaccine rejection rate.[28],[35] Also, as a result of meta-analysis, sex and residential area were found to be related. Urban areas had higher vaccine acceptance rates than rural areas, and male-dominated areas had higher vaccine acceptance rates than female-dominated areas. In addition, as a result of analysis according to the study period, it was found that the vaccine acceptance rate decreased over time. This can also be considered to be an advantage of the meta-analysis because it is a factor that cannot be known by individual surveys.

Many studies had limits of analysing only the acceptance rate of vaccines. However, even including the fact that our study used meta-analysis further investigate and compare the actual vaccination rate, no significant correlation was found. We believe that the actual vaccination

rate tends to be determined by other external factors rather than individual opinions on vaccines in the past.

#### 4.3 The limitations of research

There are some limitations to this study. First, the included studies have generally mentioned vaccine acceptance rates, but there have been some discrepancies in defining vaccine acceptance rates. Each study showed its own definitions or various expressions such as vaccine acceptance rate, vaccine rejection rate, vaccine hesitancy, and vaccine willingness rate.

Second, the heterogeneity between results was significant, and careful interpretation is required depending on different environments. This heterogeneity may be due to differences between study designs, cultural differences, vaccination local policies, or studies of other unidentified variables. In addition, there is a possibility that there will be a double aggregated case among the included studies.

#### **5.** Conclusion

COVID-19 vaccine acceptance rates demonstrated shifts and was affected by several factors. The rates decreased over time, were lower in rural (vs. urban) settings, and were relatively low in Northern and West African countries (vs. Southern and East African countries). We also found differences in vaccine acceptance rates by some socio-demographic characteristics. Targeting these characteristics, devising strategies to improve vaccine uptake in Africa could help improve vaccination rates.

# **Capsule Summary**

This review provides that COVID-19 vaccine acceptance rates demonstrated shifts and was affected by several factors.

#### **Supplementary Materials**

S1 Table. PRISMA 2009 Checklist

#### Acknowledgements

No acknowledgements.

# **Author Contribution**

Dr JIS had full access to all of the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. All authors approved the final version before submission. Study concept and design: YK, WW, and JIS; Acquisition, analysis, or interpretation of data: YK, WW, and JIS; Drafting of the manuscript: YK, WW, and JIS; Critical revision of the manuscript for important intellectual content: all authors; Statistical analysis: YK, WW, and JIS; Study supervision: JIS. JIS supervised the study and is guarantor for this study. The corresponding author attests that all listed authors meet authorship criteria and that

no others meeting the criteria have been omitted.

# Funding

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HV22C0233). The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

# **Conflicts of Interest**

The authors have no conflicts of interest to declare for this study.

# **Provenance and peer review**

Not commissioned; externally peer reviewed.

# References

- COVID-19 Map [Internet]. Johns Hopkins Coronavirus Resource Center. [cited 2022 Aug 22]. Available from: https://coronavirus.jhu.edu/map.html
- Africa CDC COVID-19 Daily Updates [Internet]. Africa CDC. [cited 2023 Mar 13]. Available from: https://africacdc.org/covid-19/
- 3. Mutombo PN, Fallah MP, Munodawafa D, Kabel A, Houeto D, Goronga T, et al. COVID-19 vaccine hesitancy in Africa: a call to action. Lancet Glob Health. 2022 Mar;10(3):e320-1.
- 4. Rémy V, Largeron N, Quilici S, Carroll S. The economic value of vaccination: why prevention is wealth. Journal of Market Access & Health Policy. 2015;3(1):29284.
- 5. Fine P, Eames K, Heymann DL. "Herd immunity": a rough guide. Clinical Infectious Diseases. 2011;52(7):911-6.
- Sallam M. COVID-19 Vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines (Basel). 2021 Feb 16;9(2):160.
- Moher D, Liberati A, Tetzlaff J, Altman DG, Group<sup>\*</sup> P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine. 2009;151(4):264-9.
- Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus pandemic (COVID-19). Our World in Data [Internet]. 2020 Mar 5 [cited 2022 Aug 22]; Available from: https://ourworldindata.org/covid-vaccinations
- Lee SW. Regression analysis for continuous independent variables in medical research: statistical standard and guideline of Life Cycle Committee. Life Cycle [Internet]. 2022 [cited 2022 Aug 8];2. Available from: http://www.elifecycle.org/archive/view\_article?pid=lc-2-0-3
- Acheampong T, Akorsikumah EA, Osae-Kwapong J, Khalid M, Appiah A, Amuasi JH. Examining vaccine hesitancy in Sub-Saharan Africa: A survey of the knowledge and attitudes among adults to receive COVID-19 vaccines in Ghana. Vaccines. 2021 Jul 22;9(8):814.
- Ahmed MAM, Colebunders R, Gele AA, Farah AA, Osman S, Guled IA, et al. COVID-19 vaccine acceptability and adherence to preventive measures in Somalia: Results of an online survey. Vaccines. 2021 May 21;9(6):543.

- Alhassan RK, Aberese-Ako M, Doegah PT, Immurana M, Dalaba MA, Manyeh AK, et al. COVID-19 vaccine hesitancy among the adult population in Ghana: Evidence from a prevaccination rollout survey. Tropical Medicine and Health. 2021;49(1):1-13.
- Anjorin AA, Odetokun IA, Abioye AI, Elnadi H, Umoren MV, Damaris BF, et al. Will Africans take COVID-19 vaccination? Mitra P, editor. PLoS ONE. 2021 Dec 1;16(12):e0260575.
- Belsti Y, Gela YY, Akalu Y, Dagnew B, Getnet M, Abdu Seid M, et al. Willingness of Ethiopian population to receive COVID-19 vaccine. JMDH. 2021 May;Volume 14:1233-43.
- Ditekemena JD, Nkamba DM, Mutwadi A, Mavoko HM, Siewe Fodjo JN, Luhata C, et al. COVID-19 vaccine acceptance in the democratic republic of Congo: A cross-sectional survey. Vaccines. 2021 Feb 14;9(2):153.
- Dula J, Mulhanga A, Nhanombe A, Cumbi L, Júnior A, Gwatsvaira J, et al. COVID-19 vaccine acceptability and its determinants in Mozambique: An online survey. Vaccines. 2021 Jul 27;9(8):828.
- 17. Elgendy MO, Abdelrahim MEA. Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy. Journal of Medical Virology. 2021 Dec;93(12):6535-43.
- Kanyanda S, Markhof Y, Wollburg P, Zezza A. Acceptance of COVID-19 vaccines in sub-Saharan Africa: Evidence from six national phone surveys. BMJ Open. 2021 Dec;11(12):e055159.
- Kollamparambil U, Oyenubi A, Nwosu C. COVID19 vaccine intentions in South Africa: health communication strategy to address vaccine hesitancy. BMC Public Health. 2021 Dec;21(1):2113.
- McAbee L, Tapera O, Kanyangarara M. Factors associated with COVID-19 vaccine intentions in Eastern Zimbabwe: A cross-sectional study. Vaccines. 2021 Sep 29;9(10):1109.
- Omar DI, Hani BM. Attitudes and intentions towards COVID-19 vaccines and associated factors among Egyptian adults. Journal of Infection and Public Health. 2021 Oct;14(10):1481-8.
- Orangi S, Pinchoff J, Mwanga D, Abuya T, Hamaluba M, Warimwe G, et al. Assessing the level and determinants of COVID-19 vaccine confidence in Kenya. Vaccines. 2021 Aug 23;9(8):936.
- 23. Oyekale AS. Compliance indicators of COVID-19 prevention and vaccines hesitancy in Kenya: A random-effects endogenous probit model. Vaccines. 2021 Nov 19;9(11):1359.
- 24. Oyekale AS. Willingness to take COVID-19 vaccines in Ethiopia: An instrumental variable probit approach. IJERPH. 2021 Aug 24;18(17):8892.
- 25. Harrison EA, Wu JW. Vaccine confidence in the time of COVID-19. European Journal of Epidemiology. 2020;35(4):325-30.
- 26. Thunström L, Ashworth M, Finnoff D, Newbold SC. Hesitancy toward a COVID-19 vaccine. Ecohealth. 2021;18(1):44-60.
- 27. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes toward a potential SARS-CoV-2 vaccine. Ann Intern Med. 2020 Dec 15;173(12):964–73.
- 28. Robinson E, Jones A, Lesser I, Daly M. International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples. Vaccine. 2021 Apr 8;39(15):2024-34.

- 29. Peretti-Watel P, Verger P, Raude J, Constant A, Gautier A, Jestin C, et al. Dramatic change in public attitudes towards vaccination during the 2009 influenza A(H1N1) pandemic in France. Euro Surveill. 2013 Oct 31;18(44):20623.
- Shih SF, Wagner AL, Masters NB, Prosser LA, Lu Y, Zikmund-Fisher BJ. Vaccine hesitancy and rejection of a vaccine for the novel coronavirus in the United States. Front Immunol. 2021 Jun 14;12:558270.
- Callaghan T, Lueck JA, Trujillo KL, Ferdinand AO. Rural and urban differences in COVID-19 prevention behaviors. J Rural Health. 2021;37(2):287-95.
- Bean-Mayberry B, Yano EM, Mor MK, Bayliss NK, Xu X, Fine MJ. Does sex influence immunization status for influenza and pneumonia in older veterans? J Am Geriatr Soc. 2009 Aug;57(8):1427-32.
- 33. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine. 2020 Sep;26:100495.
- 34. Momplaisir FM, Kuter BJ, Ghadimi F, Browne S, Nkwihoreze H, Feemster KA, et al. Racial/ethnic differences in COVID-19 vaccine hesitancy among health care workers in 2 large academic hospitals. JAMA Netw Open. 2021 Aug 2;4(8):e2121931.
- Biswas MdR, Alzubaidi MS, Shah U, Abd-Alrazaq AA, Shah Z. A Scoping review to find out worldwide COVID-19 vaccine hesitancy and its underlying determinants. Vaccines (Basel). 2021 Oct 25;9(11):1243.